Integer Holdings Corporation logo
Integer Holdings Corporation ITGR
$ 125.26 0.16%
report update icon

Quarterly report 2026-Q2
added 08-04-2026

Integer Holdings Corporation Income Statement 2025-2009 | ITGR

Brief overview of financial performance at Integer Holdings Corporation

The figures are compared over a five-year interval. Revenue at Integer Holdings Corporation moved from $1.1 billion in 2020 to $1.9 billion in 2025. The five-year change reached +72.7%, while CAGR stood at 11.5%. The company expanded its sales base at a healthy rate.

The five-year change in gross profit reached +75.1%: from $286 million to $500 million. Direct costs broadly followed the top-line trend. Comparing the endpoints gives gross margins of 26.6% and 27%. There was no meaningful shift in gross profitability.

Over the period, EBITDA shifted from $200 million to $352 million, a change of +76%. Operating performance was consistent with the change in sales. EBITDA margin was 18.6% at the start and 19% at the end. The operating margin showed no pronounced shift.

The five-year change in net income was +33.1%: from $77.3 million to $103 million. The final result remained comparatively stable.

The five-year change in capitalization reached +2.8%: from 2.9 billion dollars to 3 billion dollars. The market did not materially reprice the business.

Financial takeaway

The five-year financial profile is predominantly positive. The positive side is supported by steady gross profitability, revenue expansion and net-income growth. Further direction will depend on top-line growth, operating profitability, and net income.

Annual Income Statement Integer Holdings Corporation

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009

Market Cap

2.98 B 4.58 B 3.34 B 2.44 B 2.77 B 2.9 B 2.86 B 2.61 B 1.63 B 1.02 B 1.26 B 1.08 B - 639 M 539 M 442 M -

Shares

34.7 M 33.6 M 33.3 M 33.1 M 33 M 32.8 M 32.6 M 32.6 M 32.1 M 26.4 M 26 M 25.3 M - 23.6 M 23.6 M 23.1 M -

Historical Prices

85.7 136 100 73.6 83.9 88.2 90.2 91 51 36.1 37.8 53.1 43.3 27.1 24.8 19.1 19.2

Net Income

103 M 120 M 90.6 M 66.4 M 96.8 M 77.3 M 96.3 M 168 M 66.7 M -7.59 M 55.5 M 36.3 M - -4.8 M 33.1 M 33.1 M -

Revenue

1.85 B 1.72 B 1.56 B 1.33 B 1.22 B 1.07 B 1.26 B 1.22 B 1.14 B 800 M 688 M 664 M - 646 M 569 M - -

Cost of Revenue

1.35 B 1.26 B 1.15 B 986 M 884 M 788 M 903 M 852 M 782 M 738 M 456 M 445 M - 445 M 388 M 360 M -

Gross Profit

500 M 459 M 410 M 346 M 337 M 286 M 355 M 363 M 354 M 235 M 231 M 219 M - 202 M 180 M 174 M -

Operating Income

221 M 208 M 163 M 113 M 136 M 121 M 158 M 156 M 126 M 92.9 M 75.7 M 61.3 M - 25.8 M 61.7 M 69 M -

Interest Expense

-53.2 M -3.52 M 53.4 M 38.6 M 31.6 M 38.2 M 52.5 M 99.3 M 64 M 68.3 M 4.25 M 11.3 M - 18.1 M 16.9 M 18.5 M -

EBITDA

352 M 319 M 262 M 205 M 217 M 200 M 244 M 278 M 228 M 57.8 M 113 M 97.3 M - 72.2 M 109 M 105 M -

Operating Expenses

279 M 251 M 247 M 233 M 201 M 165 M 189 M 173 M 228 M 222 M 156 M 158 M - 176 M 119 M 105 M -

General and Administrative Expenses

212 M 185 M 173 M 158 M 141 M 109 M 139 M 116 M 120 M 92.8 M 83.6 M 82.3 M - 74.8 M 72.5 M 64.5 M -

All numbers in USD currency

Quarterly Income Statement Integer Holdings Corporation

2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

34 M 34.3 M 34.3 M 35.1 M 35 M 33.9 M 33.5 M 33.7 M 33.6 M 33.5 M 33.3 M 33.3 M 33.3 M 33.3 M 33.2 M 33.1 M 33.1 M 33.1 M 33.1 M 33 M 33 M 33 M 32.9 M 32.9 M 32.8 M 32.8 M 32.7 M 32.7 M 32.6 M 32.5 M 32.5 M 32.2 M 32 M 31.9 M 31.9 M 31.6 M 31.3 M 31 M 30.9 M 30.8 M 30.8 M 30.7 M 25.1 M 25.5 M 25.5 M 25.3 M 24.4 M 24.9 M 24.8 M 24.6 M - 24 M 23.9 M 23.8 M 23.7 M 23.6 M 23.6 M 23.4 M 23.4 M 23.3 M 23.2 M 23.2 M

Net Income

23.6 M 16.5 M - 39.7 M 37 M -22.5 M - 35.4 M 31.2 M 20.5 M - 27.3 M 24 M 13.1 M - 16.1 M 20.8 M 11.4 M - 22.1 M 29.4 M 21.5 M - 30.3 M 389 K 31.1 M 11 M 30.6 M 33.1 M 21.7 M 19.2 M -8.3 M 23.1 M 13.1 M 54.7 M 19.9 M 9.56 M 2.95 M 7.93 M 11.5 M -770 K -12.7 M 14.2 M 22 K 9.28 M 8.01 M 9.78 M 14 M 12.3 M 14.9 M - 11.1 M 9.75 M 5.66 M -5.56 M -7.56 M 3.85 M 4.47 M 5.64 M 6.99 M 8.55 M 11.9 M

Revenue

464 M 440 M - 468 M 476 M 437 M - 431 M 428 M 408 M - 397 M 400 M 379 M - 343 M 350 M 311 M - 306 M 312 M 290 M 269 M 236 M 240 M 328 M 326 M 304 M 314 M 315 M 303 M 305 M 314 M 382 M 390 M 363 M 281 M 345 M 360 M 347 M 348 M 332 M 170 M 147 M 175 M 161 M 177 M 172 M 172 M 174 M - 168 M 171 M 148 M 159 M 161 M 167 M 159 M 142 M 132 M 147 M 149 M

Cost of Revenue

351 M 330 M - 342 M 347 M 317 M - 315 M 311 M 300 M - 292 M 294 M 282 M - 256 M 257 M 229 M - 224 M 223 M 206 M - 178 M 182 M 232 M - 210 M 217 M 226 M - 213 M 216 M 209 M - 197 M 192 M 254 M - 249 M 252 M 241 M - 95 M 117 M 109 M - 114 M 114 M 117 M - 112 M 114 M 99.5 M - 110 M 115 M 112 M - 89.8 M 99.9 M 102 M

Gross Profit

113 M 110 M - 126 M 129 M 120 M - 117 M 117 M 108 M - 105 M 106 M 96.7 M - 86.7 M 92.9 M 81.5 M - 81.9 M 88.7 M 84.5 M 73.2 M 57.9 M 57.9 M 96.7 M 76 M 93.4 M 97 M 88.6 M 88.4 M 91.9 M 98.8 M 83.5 M 93.6 M 89.2 M 89.2 M 82 M 92.9 M 97.9 M 96 M 91.5 M 57.2 M 51.6 M 58 M 52.4 M 57.4 M 58.1 M 58.5 M 57.6 M - 55.9 M 57.3 M 48.7 M 51.9 M 51 M 51.9 M 46.9 M 44.7 M 41.9 M 46.6 M 47.2 M

Operating Income

34.5 M 31.9 M - 56.4 M 59.3 M 49.6 M - 58 M 54.5 M 38.7 M - 48.8 M 41.6 M 34.2 M - 29.3 M 32.7 M 22.5 M - 33.1 M 39.4 M 34.6 M - 39.8 M 9.18 M 44.1 M - 46.5 M 49.3 M 39.2 M - 41.5 M 44.4 M 30 M - 35.8 M 36.1 M 26.5 M - 36.9 M 29.3 M 11.1 M - 1.2 M 13 M 9.39 M - 16.2 M 19.5 M 22.5 M - 17 M 17.1 M 14.3 M - 2.13 M 11.1 M 11.2 M - 12.9 M 18.3 M 18 M

Interest Expense

-1.14 M -316 K - -1.13 M -3.98 M -47.9 M - -916 K 127 K -1.01 M - -580 K -359 K 17.3 M - 10.7 M 7.77 M 5.97 M - 10.1 M 7.53 M 8.53 M - 9.37 M 9.27 M 10.4 M - 12.3 M 13.6 M 13.8 M - 54.5 M 15.2 M 15.6 M - 15.8 M 15.1 M 28.9 M - 27.9 M 27.9 M 27.6 M - 5.82 M 1.21 M 1.12 M - 1.05 M 1.07 M 1.08 M - 1.52 M 1.44 M 6.99 M - 4.4 M 4.42 M 4.36 M - 4.12 M 4.4 M 4.27 M

EBITDA

104 M 66.9 M - 72.7 M 75.5 M 79.4 M - 71.6 M 68.1 M 64.9 M - 61.8 M 54.7 M 58.3 M - 41.4 M 45 M 45 M - 93.6 M 49.7 M 54.9 M - 98.8 M 48.3 M 63.6 M - 104 M 87.9 M 58.8 M - 110 M 92.9 M 56.4 M - 110 M 85.5 M 51.2 M - 104 M 74.3 M 33.5 M - 28.1 M 31.2 M 18.6 M - 44.1 M 38.1 M 31.8 M - 43.7 M 35 M 23.1 M - 36.2 M 33.2 M 22.3 M - 40 M 36.3 M 26.8 M

Operating Expenses

78.4 M 77.7 M - 69.7 M 69.8 M 70.8 M - 58.6 M 62.9 M 69.6 M - 56.2 M 64.2 M 62.5 M - 57.5 M 60.2 M 59 M - 48.8 M 49.4 M 49.9 M - 18.2 M 48.7 M 52.6 M - 46.9 M 47.6 M 49.4 M - 50.5 M 54.4 M 53.5 M - 53.4 M 53.1 M 64.7 M - 61 M 66.8 M 80.3 M - 50.5 M 44.9 M 43 M - 41.9 M 38.9 M 35.1 M - 38.9 M 40.2 M 34.4 M - 48.8 M 40.8 M 35.7 M - 29 M 28.3 M 29.2 M

General and Administrative Expenses

57.7 M 58.7 M - 50.5 M 52.9 M 51.2 M - 44.8 M 46.5 M 46.4 M - 41.4 M 45.8 M 41.9 M - 38.2 M 41.8 M 39.6 M - 34.3 M 35.4 M 35.5 M - 3.61 M 33.9 M 36.5 M - 32.9 M 33.1 M 35 M - 34.1 M 36.8 M 36.4 M - 35.1 M 35.1 M 39.5 M - 36.3 M 37.6 M 41.9 M - 22.3 M 24.1 M 22.6 M - 22.1 M 21.9 M 21.8 M - 21.6 M 22.2 M 20.1 M - 20.3 M 20.7 M 19 M - 17.8 M 17.6 M 18.6 M

All numbers in USD currency

The income statement is one of the three key financial reports of a company Integer Holdings Corporation (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
Second Sight Medical Products Second Sight Medical Products
EYES
- -0.97 % $ 54.4 M usaUSA
EDAP TMS S.A. EDAP TMS S.A.
EDAP
- - $ 162 M franceFrance
GenMark Diagnostics, Inc. GenMark Diagnostics, Inc.
GNMK
- - $ 1.77 B usaUSA
Lianluo Smart Limited Lianluo Smart Limited
LLIT
- 24.59 % $ 44.8 M chinaChina
Obalon Therapeutics, Inc. Obalon Therapeutics, Inc.
OBLN
- -5.86 % $ 30.6 M usaUSA
Aziyo Biologics Aziyo Biologics
AZYO
- 1.37 % $ 20.5 M usaUSA
AxoGen AxoGen
AXGN
$ 48.73 1.42 % $ 2.24 B usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
BioSig Technologies BioSig Technologies
BSGM
- 37.08 % $ 85.7 M usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
CHF Solutions, Inc. CHF Solutions, Inc.
CHFS
- 1.15 % $ 34.5 M usaUSA
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
Integra LifeSciences Holdings Corporation Integra LifeSciences Holdings Corporation
IART
$ 18.34 0.55 % $ 1.41 B usaUSA
BIOLASE BIOLASE
BIOL
- -13.19 % $ 166 K usaUSA
Soliton, Inc. Soliton, Inc.
SOLY
- -1.42 % $ 435 M usaUSA
Hancock Jaffe Laboratories, Inc. Hancock Jaffe Laboratories, Inc.
HJLI
- -1.98 % $ 98.3 M usaUSA
Itamar Medical Ltd. Itamar Medical Ltd.
ITMR
- 0.03 % $ 1.58 B israelIsrael
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
IRIDEX Corporation IRIDEX Corporation
IRIX
$ 0.86 3.87 % $ 14.6 M usaUSA
Misonix, Inc. Misonix, Inc.
MSON
- - $ 462 M usaUSA
Dynatronics Corporation Dynatronics Corporation
DYNT
- 14.99 % $ 929 K usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
Cutera Cutera
CUTR
- -10.19 % $ 1.99 M usaUSA
Eargo Eargo
EAR
- - $ 10.2 M usaUSA
Intersect ENT, Inc. Intersect ENT, Inc.
XENT
- - $ 955 M usaUSA
GBS GBS
GBS
- -0.57 % $ 7.12 M usaUSA
LivaNova PLC LivaNova PLC
LIVN
$ 82.22 0.02 % $ 4.48 B britainBritain
LENSAR LENSAR
LNSR
$ 8.2 0.24 % $ 98.1 M usaUSA
Avanos Medical Avanos Medical
AVNS
$ 24.99 - $ 1.16 B usaUSA
Invacare Corporation Invacare Corporation
IVC
- - $ 24.7 M usaUSA
MiMedx Group MiMedx Group
MDXG
$ 4.27 1.67 % $ 631 M usaUSA
ClearPoint Neuro ClearPoint Neuro
CLPT
$ 15.34 0.1 % $ 434 M usaUSA
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
Cytosorbents Corporation Cytosorbents Corporation
CTSO
$ 0.4 10.38 % $ 24.9 M usaUSA
SmileDirectClub SmileDirectClub
SDC
- -53.45 % $ 9.71 M usaUSA
Sientra Sientra
SIEN
- -16.59 % $ 10.3 M usaUSA
Silk Road Medical, Inc Silk Road Medical, Inc
SILK
- - $ 1.07 B usaUSA
NanoVibronix NanoVibronix
NAOV
- - $ 1.08 M usaUSA
Surgalign Holdings Surgalign Holdings
SRGA
- -32.98 % $ 1.68 M usaUSA
ShockWave Medical ShockWave Medical
SWAV
- - $ 12.3 B usaUSA
Inogen Inogen
INGN
$ 5.75 0.17 % $ 153 M usaUSA
NuVasive NuVasive
NUVA
- - $ 2.07 B usaUSA
Natus Medical Incorporated Natus Medical Incorporated
NTUS
- 1.94 % $ 1.05 B usaUSA
Nevro Corp. Nevro Corp.
NVRO
- - $ 217 M usaUSA
ThermoGenesis Holdings ThermoGenesis Holdings
THMO
- -25.84 % $ 171 K usaUSA
Talis Biomedical Corporation Talis Biomedical Corporation
TLIS
- 3.55 % $ 7.96 M usaUSA
Titan Medical Titan Medical
TMDI
- -26.32 % $ 19.6 M canadaCanada
Butterfly Network Butterfly Network
BFLY
$ 8.84 0.79 % $ 2.18 B usaUSA
Vapotherm Vapotherm
VAPO
- 6.72 % $ 34 M usaUSA